Life sciences firm Danaher is well positioned to ‌benefit as drugmakers increasingly adopt artificial intelligence to develop new medicines, its chief executive said on Wednesday, calling it a major long-term opportunity.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in